| 產(chǎn)品編號 | bsm-52198R |
| 英文名稱 | Phospho-RPS6KA1 (Thr359 + Ser363) Recombinant Rabbit mAb |
| 中文名稱 | 磷酸化絲氨酸/蘇氨酸激酶p90RSK蛋白重組兔單抗 |
| 別 名 | phospho-RPS6KA1(Thr359/Ser363); RSK1 p90(T359+S363); RSK1 p90(phospho T359+S363); p-RSK1 p90(phospho T359+S363); KS6A1_HUMAN; Ribosomal protein S6 kinase alpha-1; EC:2.7.11.1; MAPKAPK1A; RSK1; S6K-alpha-1; 90 kDa ribosomal protein S6 kinase 1(p90-RSK 1; p90RSK1; p90S6K); MAP kinase-activated protein kinase 1a(MAPK-activated protein kinase 1a; MAPKAP kinase 1a; MAPKAPK-1a); Ribosomal S6 kinase 1(RSK-1); ribosomal protein S6 kinase A1; RSK; HU-1; p90Rsk; MAPKAPK1; RSK1 p90; |
| 產(chǎn)品類型 | 磷酸化抗體 重組兔單抗 |
| 研究領域 | 腫瘤 免疫學 信號轉導 細胞凋亡 轉錄調節(jié)因子 激酶和磷酸酶 |
| 抗體來源 | Rabbit |
| 克隆類型 | Recombinant |
| 克 隆 號 | 8H2 |
| 交叉反應 | (predicted: Human,Mouse,Rat) |
| 產(chǎn)品應用 | WB=1:1000-2000,IHC-P=1:100-500,IHC-F=1:50-200,IF=1:50-200,ICC/IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 81 kDa |
| 檢測分子量 | 90 |
| 細胞定位 | 細胞核 細胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated Synthesised phosphopeptide derived from human RPS6KA1 around the phosphorylation site of Thr359/Ser363: SR(p-T)PKD(p-S)PG |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Rsk1 is a member of a family of 90kDa ribosomal protein S6 kinases, which includes Rsk1, Rsk2 and Rsk3. These are broadly expressed serine/threonine protein kinases activated in response to mitogenic stimuli, including extracellular signal regulated protein kinases Erk1 and Erk2. Rsk1 is activated by MAPK in vitro and in vivo via phosphorylation. Active Rsks appear to play a major role in transcriptional regulation by translocating to the nucleus and phosphorylating c Fos and CREB. Function: Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1. In fibroblast, is required for EGF-stimulated phosphorylation of CREB1, which results in the subsequent transcriptional activation of several immediate-early genes. In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP. Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity. Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the preinitiation complex. In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation. Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway. Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function. Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression. Subunit: Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 in quiescent cells. Transiently dissociates following mitogenic stimulation. Interacts with ETV1/ER81 and FGFR1. Subcellular Location: Nucleus. Cytoplasm. Post-translational modifications: Activated by phosphorylation at Ser-221 by PDPK1. Autophosphorylated on Ser-380, as part of the activation process. May be phosphorylated at Thr-359 and Ser-363 by MAPK1/ERK2 and MAPK3/ERK1. N-terminal myristoylation results in an activated kinase in the absence of added growth factors. Similarity: Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. S6 kinase subfamily. Contains 1 AGC-kinase C-terminal domain. Contains 2 protein kinase domains. Gene ID: 6195 Database links: Entrez Gene: 6195 Human Entrez Gene: 20111 Mouse Omim: 601684 Human SwissProt: Q15418 Human SwissProt: P18653 Mouse Unigene: 149957 Human Unigene: 301827 Mouse Unigene: 34915 Rat |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
